PRESENTATION

Q1 2024 — Presentation

Q1 2024PDF · 12 pages187 KB
Elevance Health
1Q 2024 Earnings Presentation
April 18, 2024

-- 1 of 12 --

2
Key Highlights
• 	Elevance Health delivered a solid start to the year, reflecting disciplined execution of our strategic
initiatives across our diversified portfolio of businesses
• 	1Q 2024 adjusted diluted EPS of $10.64 grew 12.5% year-over-year
• 	1Q 2024 adjusted operating gain of $3.1B grew 7.3% year-over-year
1Q 2024 Results
1
• 	2024 adjusted diluted EPS guidance raised to >$37.20, reflecting growth of at least 12% year-over-year
• 	Significant progress in executing on our enterprise strategy, accelerating capabilities and services in
Carelon, and scaling our enterprise flywheel for growth
• 	Optimizing our Health Benefits business through ongoing margin recovery in our commercial business;
maximizing access to care for Medicaid members subject to eligibility redeterminations; investing in a
strong foundation for profitable and sustainable growth in our Medicare Advantage business; and
implementing disciplined operating expense management
2024 Outlook
2
• 	Announced the next step in our journey to expand access to high-quality, patient-centered value-based
care in our local markets through a strategic partnership with Clayton, Dubilier & Rice
• 	Building a payor-agnostic, advanced primary care and physician enablement business serving consumers
across commercial, Medicare and Medicaid health plans
Strategic Priorities
3

-- 2 of 12 --

33
Key Highlights
• 	Elevance Health delivered first
quarter results slightly ahead of
internal expectations
• 	Solid performance in both Health
Benefits and Carelon businesses
• 	Operating revenue of $42.3B
consistent with expectations
• 	Benefit expense ratio of 85.6%
improved 20 basis points driven by
premium yields, including
disciplined commercial
underwriting
• 	Adjusted operating gain grew 7.3%;
Health Benefits and Carelon
contributed $138M and $72M of
operating gain growth, respectively
1Q 2024 Results
Change (%/bps)	1Q 2023	1Q 2024	Elevance Health
0.9%	$41.9B	$42.3B	Operating Revenue 1
(20) bps	85.8%	85.6%	Medical Loss Ratio
0 bps	11.4%	11.4%	Adjusted Operating Expense Ratio1,2
7.3%	$2.9B	$3.1B	Adjusted Operating Gain1,2
50 bps	6.8%	7.3%	Adjusted Operating Margin 1,2
20.2%	$387M	$465M	Net Investment Income
12.5%	$9.46	$10.64	Adjusted diluted EPS
($4.5B)	$6.5B	$2.0B	Operating Cash Flow
1. 	See “Basis of Presentation” on page 9 herein.
2. 	See “GAAP Reconciliation” on pages 10 and 11 herein.

-- 3 of 12 --

44
Key Highlights
• 	Health Benefits delivered solid
results
• 	Operating revenue reflects
expected attrition in Medicaid
membership, mostly offset by
premium rate increases to cover
medical cost trends
• 	Operating gain increased 6.4%
driven by improved premium yields,
including disciplined underwriting
practices
• 	Operating margin expanded 30
basis points, led by the continued
recovery of commercial margins
• 	Membership of 46.2M reflects
expected attrition in Medicaid and
ongoing momentum in commercial
fee-based and risk-based
membership
Change (%/bps)	1Q 2023	1Q 2024	Health Benefits
(0.1%)	$37.3B	$37.3B	Operating Revenue 1
6.4%	$2.1B	$2.3B	Operating Gain1
30 bps	5.8%	6.1%	Operating Margin 1
(3.9%)	48.1M	46.2M	Membership
1. 	See “Basis of Presentation” on page 9 herein.
Health Benefits
1Q 2024 Results

-- 4 of 12 --

55
Key Highlights
• 	Carelon scaling diverse array of
businesses
• 	Serves as the enterprise flywheel for
growth, integrating physical,
behavioral, social and pharmacy
services to deliver whole health,
affordably
• 	CarelonRx operating revenue of $8.1
billion developed in line with
expectations; operating gain of $523
million, up 2%
• 	CarelonRx scaling BioPlus,
integrating Paragon Healthcare,
announces acquisition of Kroger
Specialty Pharmacy
• 	Carelon Services operating revenue
of $4.0 billion grew 16%; operating
gain of $290 million, up 27%, driven
by improved performance on risk-
based arrangements
1Q 2024 Results
Change (%/bps)	1Q 2023	1Q 2024	Carelon
5.2%	$11.5B	$12.1B	Operating Revenue 1
9.7%	$741M	$813M	Operating Gain1
20 bps	6.5%	6.7%	Operating Margin 1
1.7%	75.7M	77.0M	Adjusted Scripts
(1.1%)	104.0M	102.9M	Consumers Served
1. 	See “Basis of Presentation” on page 9 herein.
Health Services

-- 5 of 12 --

66
Flywheel Supports Sustainable, Long-Term Growth
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Long-Term Adjusted Earnings Per Share
Compound Annual Growth Rate Target of At Least 12%
Over 46M medical members balanced
across commercial, Medicaid and
Medicare, leveraging the assets and
capabilities of Carelon to accelerate
growth
Integrated portfolio of whole health
solutions connecting care across
physical, behavioral, social, and
pharmacy needs to bend the cost
curve, enhance consumer experiences,
and deliver whole health, affordably
Health Services

-- 6 of 12 --

77
Committed to Strong Growth Over the Long-Term
M&A/ Reinvest
in Core
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2022 	2027
Target
$156B
Upper Single
to Low Double
Digit CAGR2
2022 	2027
Target
Elevance Health
5.8%
Mid to Upper
Single Digit
2022 	2027
Target
$41B
Mid Teens
CAGR2
2022 	2027
Target
Carelon 3
4.3%
5.5% – 6.5%
2022 	2027
Target
$138B
Upper Single
Digit CAGR2
2022 	2027
Target
Health Benefits
Capital
Allocation
Long-Term Adjusted Earnings Per Share Compound
Annual Growth Rate Target of At Least 12%
Operating
Margin 1
Revenue1
(in Billions)
1. 	2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials.
2. 	Five-Year Compound Annual Growth Rate target for 2022 – 2027.
3. 	The compound annual growth rate (CAGR) target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR
and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services.

-- 7 of 12 --

8
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our
views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial
projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services;
and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our
control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in
existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products
and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy,
data or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market
conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and
develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the
complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and
funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation,
government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our
information systems; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability
claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint
ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets;
possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock
and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount
of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in
our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our
licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws
and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

-- 8 of 12 --

9
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on the last page of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 9 of 12 --

10	10
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share
Three Months Ended Mar 31
Change	2023	2024	(In millions, except per share data)
12.9%	$1,989	$2,246	Shareholders' net income
Add / (Subtract):
113	161	Net losses on financial instruments
235	116	Amortization of other intangible assets
26	52	Transaction and integration related costs1
1	2	Litigation expenses1
—	(4)	Business optimization charges 1
(97)	(81)	Tax impact of non-GAAP adjustments
278	246	Net adjustment items
9.9%	$2,267	$2,492	Adjusted shareholders' net income
15.5%	$8.30	$9.59	Shareholders’ earnings per diluted share
Add / (Subtract):
0.47	0.69	Net losses on financial instruments
0.98	0.50	Amortization of other intangible assets
0.11	0.22	Transaction and integration related costs1
—	0.01	Litigation expenses1
—	(0.02)	Business optimization charges 1
(0.40)	(0.35)	Tax impact of non-GAAP adjustments
1.16	1.05	Net adjustment items
12.5%	$9.46	$10.64	Adjusted shareholders’ earnings per diluted share
Three Months Ended Mar 31
Change	2023	2024	(In millions)
12.2%	$2,619	$2,939	Income before income tax expense
(387)	(465)	Net investment income
113	161	Net losses on financial instruments
251	265	Interest expense
235	116	Amortization of other intangible assets
6.5%	$2,831	$3,016	Reportable segments operating gain
1. 	Adjustment item resides in the Corporate & Other reportable segment.

-- 10 of 12 --

11	11
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2024 Outlook
Three Months Ended Dec 31
Change	2022	2023	(In millions)
1.8%	$4,800	$4,886	Operating expense
Add / (Subtract):
(26)	(52)	Transaction and integration related costs1
(1)	(2)	Litigation expenses1
—	4	Business optimization charges 1
(27)	(50)	Net adjustment items
1.3%	$4,773	$4,836	Adjusted operating expense
0.9%	$41,898	$42,273	Operating revenue
10 bp	11.5%	11.6%	Operating expense ratio
— bp	11.4%	11.4%	Adjusted operating expense ratio
Three Months Ended Mar 31
Change	2023	2024	(In millions)
6.5%	$2,831	$3,016	Reportable segments operating gain
Add / (Subtract):
26	52	Transaction and integration related costs1
1	2	Litigation expenses1
—	(4)	Business optimization charges 1
27	50	Net Adjustment Items
7.3%	$2,858	$3,066	Reportable segments operating gain
Full Year 2024
Outlook
Greater than $34.05	Shareholders’ earnings per diluted share
Add / (Subtract):
$1.93	Amortization of other intangibles
$1.35	Net losses on financial instruments
$0.75	Transaction and integration related costs1
$0.03	Litigation expenses1
($0.02)	Business optimization charges 1
Approximately ($0.89)	Tax impact of non-GAAP adjustments
$3.15	Net adjustment items
Greater than $37.20	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Corporate & Other reportable segment.

-- 11 of 12 --



-- 12 of 12 --